Travere Therapeutics Announces Positive Topline Results from Cohort 6 in the Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria
May 31, 2023 07:00 ET
|
Travere Therapeutics, Inc.
Data from the four patients treated with the highest dose of pegtibatinase showed a clinically meaningful 67.1% mean relative reduction in total homocysteine from baseline Pegtibatinase has...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 11, 2023 17:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May 10, 2023, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics Reports First Quarter 2023 Financial Results
May 04, 2023 16:01 ET
|
Travere Therapeutics, Inc.
FILSPARI™(sparsentan) granted accelerated approval by FDA for the reduction of proteinuria in IgA nephropathy (IgAN) on February 17th, 2023; commercial launch underway Total net product sales of...
Travere Therapeutics Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
May 01, 2023 16:05 ET
|
Travere Therapeutics, Inc.
The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints trended favorably for sparsentan Treatment with...
Travere Therapeutics to Report First Quarter 2023 Financial Results
April 26, 2023 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, April 26, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2023 financial results on Thursday, May 4, 2023, after the close...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 13, 2023 17:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, April 13, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on April 10, 2023, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023
April 01, 2023 04:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, April 01, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced publication in The Lancet of the interim analysis of efficacy and safety data from the ongoing...
Travere Therapeutics to Present at Upcoming Investor Conferences
March 28, 2023 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, March 28, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming conferences: Guggenheim...
Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023
March 23, 2023 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the interim analysis of efficacy and safety data from the ongoing Phase 3 PROTECT Study...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 14, 2023 17:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on March 10, 2023, the Compensation Committee of its Board of Directors granted...